Market Place
Sourcing Support
BDR Pharma introduces prostate cancer treatment drug in oral solution form
02 Jan 2024 //
ECONOMIC TIMES
BDR Pharma launches Dalbonova Injection for acute bacterial skin infections
28 Aug 2023 //
EXPRESSPHARMA
BDR Pharmaceutical launches generic drug for treating prostate cancer in India
03 Jan 2023 //
ECONOMICTIMES
BDR Pharma partners with Varenyam Healthcare to launch Sugmadex in India
31 May 2022 //
EXPRESS PHARMA
BDR Pharma raises Rs 685 crore from multiples, other investors
17 May 2022 //
ECONOMIC TIMES
BDR Pharma to commercialise Furmecil, for advanced gastric cancer
20 Apr 2022 //
ET HEALTH
CCI approves deal to acquire minority stake in BDR Pharmaceuticals
18 Apr 2022 //
BUSINESS-STANDARD
BDR looking to buy majority stake in drug plant in Belarus
03 Mar 2022 //
ECONOMIC TIMES
BDR Pharma introduces prostate cancer drug with enhanced strength
28 Feb 2022 //
BUSINESS-STANDARD
Mankind Pharma and BDR Pharma come together to launch Molulife (Molnupiravir)
29 Dec 2021 //
EXPRESSPHARMA
BDR Pharmaceuticals launches India’s first generic Midostaurin Leukemia
14 Dec 2021 //
FINANCIALEXPRESS
BDR launches India’s first generic Midostaurin (MSTARIN) to treat Leukemia
07 Dec 2021 //
EXPRESS PHARMA
BDR Pharma launches biapenem to treat various indications
24 Sep 2021 //
PHARMABIZ
BDR Pharma launches cabozantinib to treat metastatic medullary thyroid cancer
14 Sep 2021 //
PHARMABIZ
BDR Pharma license agreement with DRDO for manufacturing Covid-19 Drug 2-DG
26 Jul 2021 //
PHARMABIZ
BDR Pharmaceuticals in license pact with DRDO for manufacturing 2-DG Covid drug
26 Jul 2021 //
LIVEMINT
BDR Pharmaceuticals in license pact with DRDO for manufacturing 2-DG Covid drug
26 Jul 2021 //
BUSINESS-STANDARD
BDR Pharma license agreement with DRDO for manufacturing Covid-19 Drug 2-DG
26 Jul 2021 //
PHARMABIZ
BDR Pharmaceuticals in license pact with DRDO for manufacturing 2-DG Covid drug
26 Jul 2021 //
LIVEMINT
BDR Pharmaceuticals in license pact with DRDO for manufacturing 2-DG Covid drug
26 Jul 2021 //
BUSINESS-STANDARD
BDR Pharma license agreement with DRDO to manufacture 2-DGÂ drug in India
26 Jul 2021 //
EXPRESS PHARMA
BDR Pharma inks license agreement with DRDO to produce COVID-19 drug 2-DG
26 Jul 2021 //
ECONOMIC TIMES
BDR Pharma launches the first generic RUCAPARIB to treat advanced ovarian
27 May 2021 //
ECONOMICTIMES
BDR Pharma launches generic cancer drug in India
20 Oct 2020 //
ECONOMICTIMES
BDR launches 80mg version of prostate cancer drug at Rs 24,480 per pack in India
21 Sep 2020 //
ECONOMIC TIMES
BDR Pharma to invest in backward integration to create huge KSM & API facilities
18 Sep 2020 //
PHARMABIZ
BDR Pharma to launch 400mg Favipiravir tablets for treating patients in India
05 Sep 2020 //
ECONOMIC TIMES
BDR Pharma to launch 400mg Favipiravir tablets for treating coronavirus patients
04 Sep 2020 //
ECONOMICTIMES
BDR launches Favipiravir under brand name `BDFAVI` at Rs 63 per tablet in India
05 Aug 2020 //
ECONOMICTIMES
BDR launches Favipiravir under brand name `BDFAVI` at Rs 63 per tablet in India
04 Aug 2020 //
ECONOMICTIMES
Cipla-BDR Pharmaceuticals eyeing early approval of Favipiravir
24 Jun 2020 //
MONEYCONTROL
BDR in pact to make Gilead drug for Cipla
01 Jun 2020 //
ECONOMICTIMES
BDR Pharmaceuticals move on Remdesivir clone irks Gilead
28 May 2020 //
ECONOMIC TIMES
Carlyle in talks to invest $100 million in BDR Pharma
14 Aug 2018 //
ECONOMIC TIMES
Experts welcome India`s denial of patent to prostrate cancer drug, Xtandi
30 Nov 2016 //
PHARMABIZ
Patent denied, price of prostate cancer drug may go down
10 Nov 2016 //
ECONOMIC TIMES
Gland Chemicals Receives Written Confirmation of Export of 3 APIs to EU
20 Jan 2016 //
TWOFOUR INSIGHT
